<p>NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBY - 獲取免費報告) 的股票在週六的交易中達到了新的 52 周高點。該公司的股價最高達到 6.47 美元，最後交易價格為 5.30 美元，交易量為 30793967 股。該股票之前的收盤價為 2.95 美元。</p>
<h2>NovaBay Pharmaceuticals 股票上漲 79.7%</h2>
<p>該股票的 50 日移動平均線為 1.46 美元，200 日移動平均線為 1.25 美元。</p>
<h2>NovaBay Pharmaceuticals 宣佈分紅</h2>
<p>該公司最近還宣佈了一項分紅，已於 9 月 29 日（星期一）支付。10 月 1 日（星期三）的股東記錄獲得每股 0.80 美元的分紅。這代表了 3,791.0% 的收益率。該分紅的除息日期為 9 月 30 日（星期二）。</p>
<h2>NovaBay Pharmaceuticals 的機構交易</h2>
<p>對沖基金和其他機構投資者最近對該公司的持倉進行了調整。Ground Swell Capital LLC 在第三季度購買了價值 25,000 美元的 NovaBay Pharmaceuticals 新股份。Apollon Wealth Management LLC 在第三季度獲得了價值 35,000 美元的 NovaBay Pharmaceuticals 新頭寸。最後，C2C Wealth Management LLC 在第二季度將其在 NovaBay Pharmaceuticals 的持股增加了 78.2%。C2C Wealth Management LLC 現在擁有 98,000 股該生物製藥公司的股票，價值 57,000 美元，此前在上個季度又購買了 43,000 股。對沖基金和其他機構投資者持有該公司 23.25% 的股份。</p>
<h2>NovaBay Pharmaceuticals 公司簡介</h2>
<p>(獲取免費報告)</p>
<p>NovaBay Pharmaceuticals, Inc 是一家臨牀階段的生物技術公司，專注於開發和商業化新型非抗生素抗感染產品，旨在調節先天免疫反應。利用其專有的 Aganocide®技術，該公司的合成抗微生物化合物能夠靶向並中和病原體，而不會導致抗生素耐藥性。NovaBay 的研發工作集中在眼科、皮膚科和傷口護理應用上，旨在解決感染控制和炎症管理中的未滿足需求。</p>
<p>該公司的主要商業產品包括 Avenova®，一種用於管理慢性瞼板腺功能障礙和瞼緣炎的眼瞼和睫毛清潔溶液，以及 NeutroPhase®，一種用於急性和慢性傷口灌洗的純次氯酸傷口和皮膚清潔劑。</p>
<h2>精選故事</h2>
<ul>
<li>五隻我們更看好的股票，勝過 NovaBay Pharmaceuticals</li>
<li>如何投資生物技術股票</li>
<li>這三家銀行在年末前上漲，但這種趨勢會持續嗎？</li>
<li>什麼是盈利驚喜？</li>
<li>三隻飆升的股票剛剛獲得標準普爾 500 的最終認可</li>
<li>什麼是澳大利亞證券交易所（ASX）</li>
<li>這隻 ETF 在美聯儲降息後獲得了重大助力</li>
</ul>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 NovaBay Pharmaceuticals 嗎？</h2>
<p>在你考慮 NovaBay Pharmaceuticals 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 NovaBay Pharmaceuticals 並不在名單上。</p>
<p>雖然 NovaBay Pharmaceuticals 目前在分析師中被評為持有，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

NovaBay制藥

<p>NovaBay 製藥（NYSEAMERICAN:NBY）股票創下 52 周新高，交易價格最高達到 6.47 美元，最終收於 5.30 美元，較前一交易日的 2.95 美元上漲了 79.7%。該股票的交易量達到 30,793,967 股。公司最近宣佈每股派息 0.80 美元，收益率高達 3,791.0%。機構投資者已調整其持倉，對沖基金持有該股票的 23.25%。NovaBay 專注於非抗生素抗感染產品，利用 Aganocide®技術進行感染控制</p>

<p>NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBY - Get Free Report) shares reached a new 52-week high during trading on Saturday . The company traded as high as $6.47 and last traded at $5.30, with a volume of 30793967 shares trading hands. The stock had previously closed at $2.95.</p>
<div class="lb-trans"><p>NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBY - 獲取免費報告) 的股票在週六的交易中達到了新的 52 周高點。該公司的股價最高達到 6.47 美元，最後交易價格為 5.30 美元，交易量為 30793967 股。該股票之前的收盤價為 2.95 美元。</p>
</div><h2>NovaBay Pharmaceuticals Trading Up 79.7%</h2>
<div class="lb-trans"><h2>NovaBay Pharmaceuticals 股票上漲 79.7%</h2>
</div><p>The stock has a fifty day moving average of $1.46 and a 200-day moving average of $1.25.</p>
<div class="lb-trans"><p>該股票的 50 日移動平均線為 1.46 美元，200 日移動平均線為 1.25 美元。</p>
</div><h2>NovaBay Pharmaceuticals Announces Dividend</h2>
<div class="lb-trans"><h2>NovaBay Pharmaceuticals 宣佈分紅</h2>
</div><p>The business also recently announced a dividend, which was paid on Monday, September 29th. Shareholders of record on Wednesday, October 1st were given a dividend of $0.80 per share. This represents a yield of 3,791.0%. The ex-dividend date of this dividend was Tuesday, September 30th.</p>
<div class="lb-trans"><p>該公司最近還宣佈了一項分紅，已於 9 月 29 日（星期一）支付。10 月 1 日（星期三）的股東記錄獲得每股 0.80 美元的分紅。這代表了 3,791.0% 的收益率。該分紅的除息日期為 9 月 30 日（星期二）。</p>
</div><h2>Institutional Trading of NovaBay Pharmaceuticals</h2>
<div class="lb-trans"><h2>NovaBay Pharmaceuticals 的機構交易</h2>
</div><p>Hedge funds and other institutional investors have recently made changes to their positions in the business. Ground Swell Capital LLC purchased a new stake in shares of NovaBay Pharmaceuticals in the 3rd quarter valued at $25,000. Apollon Wealth Management LLC acquired a new position in NovaBay Pharmaceuticals during the third quarter valued at $35,000. Finally, C2C Wealth Management LLC boosted its holdings in NovaBay Pharmaceuticals by 78.2% in the second quarter. C2C Wealth Management LLC now owns 98,000 shares of the biopharmaceutical company's stock valued at $57,000 after purchasing an additional 43,000 shares during the last quarter. Hedge funds and other institutional investors own 23.25% of the company's stock.</p>
<div class="lb-trans"><p>對沖基金和其他機構投資者最近對該公司的持倉進行了調整。Ground Swell Capital LLC 在第三季度購買了價值 25,000 美元的 NovaBay Pharmaceuticals 新股份。Apollon Wealth Management LLC 在第三季度獲得了價值 35,000 美元的 NovaBay Pharmaceuticals 新頭寸。最後，C2C Wealth Management LLC 在第二季度將其在 NovaBay Pharmaceuticals 的持股增加了 78.2%。C2C Wealth Management LLC 現在擁有 98,000 股該生物製藥公司的股票，價值 57,000 美元，此前在上個季度又購買了 43,000 股。對沖基金和其他機構投資者持有該公司 23.25% 的股份。</p>
</div><h2>NovaBay Pharmaceuticals Company Profile</h2>
<div class="lb-trans"><h2>NovaBay Pharmaceuticals 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(獲取免費報告)</p>
</div><p>NovaBay Pharmaceuticals, Inc is a clinical-stage biotechnology company focused on developing and commercializing novel, non-antibiotic anti-infective products designed to regulate the innate immune response. Leveraging its proprietary Aganocide® Technology, the company's synthetic antimicrobial compounds target and neutralize pathogens without contributing to antibiotic resistance. NovaBay's research and development efforts concentrate on ophthalmic, dermatological and wound care applications, aiming to address unmet needs in infection control and inflammation management.</p>
<div class="lb-trans"><p>NovaBay Pharmaceuticals, Inc 是一家臨牀階段的生物技術公司，專注於開發和商業化新型非抗生素抗感染產品，旨在調節先天免疫反應。利用其專有的 Aganocide®技術，該公司的合成抗微生物化合物能夠靶向並中和病原體，而不會導致抗生素耐藥性。NovaBay 的研發工作集中在眼科、皮膚科和傷口護理應用上，旨在解決感染控制和炎症管理中的未滿足需求。</p>
</div><p>The company's primary commercial products include Avenova®, an eyelid and lash cleaning solution indicated for managing chronic blepharitis and meibomian gland dysfunction, and NeutroPhase®, a pure hypochlorous acid wound and skin cleanser used in acute and chronic wound irrigation.</p>
<div class="lb-trans"><p>該公司的主要商業產品包括 Avenova®，一種用於管理慢性瞼板腺功能障礙和瞼緣炎的眼瞼和睫毛清潔溶液，以及 NeutroPhase®，一種用於急性和慢性傷口灌洗的純次氯酸傷口和皮膚清潔劑。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精選故事</h2>
</div><ul>
<li>Five stocks we like better than NovaBay Pharmaceuticals</li>
<li>How to Invest in Biotech Stocks</li>
<li>These 3 Banks Are Rallying Into Year-End, But Will It Continue?</li>
<li>What is an Earnings Surprise?</li>
<li>3 Surging Stocks Just Got the Ultimate Stamp of Approval From the S&amp;P 500</li>
<li>What is the Australian Securities Exchange (ASX)</li>
<li>This ETF Caught a Major Tailwind After the Fed’s Rate Cut</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，勝過 NovaBay Pharmaceuticals</li>
<li>如何投資生物技術股票</li>
<li>這三家銀行在年末前上漲，但這種趨勢會持續嗎？</li>
<li>什麼是盈利驚喜？</li>
<li>三隻飆升的股票剛剛獲得標準普爾 500 的最終認可</li>
<li>什麼是澳大利亞證券交易所（ASX）</li>
<li>這隻 ETF 在美聯儲降息後獲得了重大助力</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in NovaBay Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 NovaBay Pharmaceuticals 嗎？</h2>
</div><p>Before you consider NovaBay Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 NovaBay Pharmaceuticals 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and NovaBay Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 NovaBay Pharmaceuticals 並不在名單上。</p>
</div><p>While NovaBay Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 NovaBay Pharmaceuticals 目前在分析師中被評為持有，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

NovaBay 製藥（NYSEAMERICAN:NBY）創下 12 個月新高 - 現在是買入的好時機嗎？